Diversity and Functions of Gaba Receptors: A Tribute to Hanns Möhler, Part B: Volume 73

ISBN-13: 9780128026588 / Angielski / Twarda / 2015 / 284 str.

Rudolph, Uwe

Opis

Diversity and Functions of GABA Receptors: A Tribute to Hanns Mohler, Part B, a new volume of Advances in Pharmacology, presents the diversity and functions of GABA Receptors. The volume looks at research performed in the past 20 years, which has revealed specific physiological and pharmacological functions of individual GABAA receptor subtypes, providing novel opportunities for drug development.

• Contributions from the best authors in the field
• An essential resource for pharmacologists, immunologists, and biochemists

Spis treści

1. Reflections on more than 30 years Association with HannsNorman G. Bowery2. Significance of GABAA Receptor Heterogeneity: Clues from Developing NeuronsJean-Marc Fritschy3. Regulation of Cell Surface GABAB Receptors: Contribution to Synaptic Plasticity in Neurological DiseasesDietmar Benke, Karthik Balakrishnan and Khaled Zemoura4. Restoring the Spinal Pain Gate: GABAA Receptors as Targets for Novel AnalgesicsHanns Ulrich Zeilhofer, William T. Ralvenius and Mario A. Acuña5. GABAergic Control of Depression-related Brain States Bernhard Luscher and Thomas Fuchs6. Mechanisms of Fast Desensitization of GABAB Receptor-Gated CurrentsAdi Raveh, Rostislav Turecek and Bernhard Bettler7. Allosteric Ligands and their Binding Sites Define ?-Aminobutyric acid (GABA) Type A Receptor SubtypesRichard W. Olsen8. Diversity in GABAergic SignalingKaspar Vogt9. The Diversity of GABAA Receptor Subunit Distribution in the Normal and Huntington's Disease Human BrainHJ Waldvogel and RLM Faull

O autorze

Dr. Rudolph is Director of the Laboratory of Genetic Neuropharmacoloy at McLean Hospital and Professor of Psychiatry at Harvard Medical School. He studied medicine and completed a research thesis on G proteins at the Freie Universitat Berlin, Germany. After postdoctoral training at Baylor College of Medicine in Houston, Texas, where he developed a mouse model of inflammatory bowel disease and colon cancer, he moved to the Institute of Pharmacology and Toxicology of the University of Zurich to work on GABAA receptors. There, he developed different lines of knock-in mice in which diazepam-sensitive GABAA receptor subtypes were rendered insensitive to diazepam by a histidine to arginine point mutation. Studying these mice enables researchers to uncover unique functional roles of GABAA receptor subtypes. In 2005, he joined McLean Hospital in Belmont, MA, and Harvard Medical School, where his research group is elucidating the functions of GABAA receptor subtypes in defined neuronal populations.